Results 51 to 60 of about 54,917 (299)
British Journal of Clinical Pharmacology, EarlyView.Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić +8 more
wiley +1 more source
SGLT2 immunofluorescence in the kidney and cochlea.
, 2014 Two different SGLT2 antibodies were used, a rabbit polyclonal IgG to synthetic peptide derived from residues 250–350 of human SGLT2 and a goat polyclonal IgG against a murine peptide sequence within the N-terminal extracellular domain of SGLT2. (A, C) In
Hongzhe Li (26250) +5 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed +7 more
wiley +1 more source
Reviews in Cardiovascular MedicineBackground: The present meta-analysis aimed to examine the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the prognosis of diabetes patients who experienced acute myocardial infarction (AMI).
Zhiwei Li +3 more
doaj +1 more source
Cardiovascular Diabetology, 2020 Background Clinical trials have shown the cardiovascular protective effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors and reduced hospitalization for heart failure. However, no study has investigated the association between SGLT2 inhibitors and
Hung-Yi Chen +3 more
doaj +1 more source
, 2018 The sodium-dependent glucose transporters 2 (SGLT2) plays important role in renal reabsorption of urinal glucose back to plasma for maintaining glucose homeostasis. The approval of SGLT2 inhibitors for treatment of type 2 diabetes highlights the SGLT2 as
Jing Hu +6 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang +5 more
wiley +1 more source
SGLT2 inhibitors: control of glycemia and nephroprotection properties
Безопасность и риск фармакотерапии, 2018 Recently were appeared a fundamentally new insulin-independent approach to the treatment of type 2 diabetes - reduce blood glucose levels by inhibiting proteins co-transporters SGLT2 (sodium glucose transporter) in the proximal tubules of the kidneys ...
A. A. Volodin +3 more
doaj
International Journal of Nephrology and Renovascular Disease, 2020 George Vasquez-Rios,1 Girish N Nadkarni1,2 1Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 2The Charles Bronfman Institute of Personalized Medicine, Icahn School of Medicine at Mount ...
Vasquez-Rios G, Nadkarni GN
doaj
SGLT2 Inhibitors and the Diabetic Kidney [PDF]
Diabetes Care, 2016 Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may ...
FIORETTO, PAOLA +4 more
openaire +3 more sources